A drug that slashed a dangerous cholesterol-like particle by as much as 80 percent still failed to stop a single extra heart attack or stroke in one of the largest cardiovascular trials ever run.
Story Snapshot
- Novartis and Ionis Pharmaceuticals announced their drug pelacarsen missed its main goal in the Lp(a)HORIZON phase III trial.
- The drug lowered lipoprotein(a), a genetic cholesterol-like particle, but did not cut heart attacks, strokes, or cardiovascular deaths.
- More than 8,300 patients with elevated lipoprotein(a) and existing heart disease took part in the study.
- The result raises hard questions about whether lowering this particle actually protects the heart at all.
What Novartis Announced and Why It Matters
Novartis said on September 4, 2026, that pelacarsen did not meet its primary goal in the Lp(a)HORIZON trial. The company had measured a combined outcome of cardiovascular death, non-fatal heart attack, non-fatal stroke, and urgent procedures to reopen blocked arteries. Compared to placebo, the drug showed no advantage on that combined measure, even though it worked exactly as designed at lowering the target particle.
Reuters reported the same day that pelacarsen did not cut the risk of major heart attacks and strokes in patients carrying this inherited risk factor. The wire service called it a setback for a closely watched experimental approach that drugmakers had hoped would open a new market for heart disease prevention.
Inside the Trial and the Particle It Targeted
Lipoprotein(a), known as Lp(a), is a cholesterol-carrying particle controlled almost entirely by genes. Diet and exercise barely touch it. Roughly one in five people carry elevated levels, and doctors have long suspected it drives heart attacks and strokes independent of regular cholesterol. Lp(a)HORIZON enrolled more than 8,300 patients with high Lp(a) and existing cardiovascular disease to test that theory directly.
Pelacarsen is an antisense drug, meaning it blocks the genetic instructions the body uses to build the particle. Earlier studies confirmed it could push Lp(a) levels down sharply and reliably. Bloomberg described the medicine as a potential blockbuster before the trial results came in, noting it represented a genuinely new approach to preventing cardiovascular disease rather than another cholesterol pill.
The Market Reaction and What Comes Next for Novartis
Novartis shares fell after the announcement as investors recalculated the value of the company’s cardiovascular pipeline. The failed trial adds pressure on Novartis to prove its other experimental drugs can deliver, especially since pelacarsen had been positioned as a flagship program tied to premium pricing expectations.
The trial had been designed years earlier specifically to answer whether reducing Lp(a) translates into fewer heart attacks, a question the broader cardiology field had flagged as unresolved even while the drug moved through development. That framing now matters more than ever, because the answer came back no.
A Familiar Pattern in Heart Drug Research
Doctors have seen this story before. A drug moves a blood marker in the right direction, hopes rise, and then a large outcomes trial finds no benefit for actual patients. One life sciences outlet quoted a researcher saying the findings simply did not show that lowering Lp(a) translated into reduced cardiovascular risk, a blunt summary of the entire episode.
Contrast that with alirocumab, a cholesterol drug tested in the earlier ODYSSEY OUTCOMES trial. That drug lowered both LDL cholesterol and Lp(a), and researchers found real reductions in heart attacks and related events. Some scientists argue the LDL effect, not the Lp(a) drop, did the heavy lifting, which is exactly the kind of confusion pelacarsen’s failure now forces experts to sort out.
For patients with high Lp(a), the practical advice has not changed much. Doctors still recommend aggressive control of LDL cholesterol, blood pressure, and other known risk factors, since those tools have proven track records. Other companies, including Amgen, are still running their own Lp(a)-lowering trials, so this single result does not close the book on the entire theory. It does, however, demand real caution before anyone assumes a lower number on a lab report guarantees a longer, healthier life.
Sources:
menshealth.com, novartis.com, reuters.com, academic.oup.com, sciencedirect.com, statnews.com
